

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130: <i>Defense Health Program I BA 2: RDT&E</i>					R-1 Program Element (Number/Name) PE 0607100DHA I <i>Medical Products and Capabilities Enhancement Activities</i>							
COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
Total Program Element	45.971	17.215	17.619	17.971	0.000	17.971	18.330	18.697	19.071	19.452	Continuing	Continuing
377A: <i>GDF-Medical Products and Capabilities Enhancement Activities</i>	45.971	17.215	17.619	17.971	0.000	17.971	18.330	18.697	19.071	19.452	Continuing	Continuing

Note

N/A

A. Mission Description and Budget Item Justification

Guidance for Development of the Force-Medical Products and Capabilities Enhancement Activities: Funds will support developmental upgrades to medical systems, training systems, and products that have been fielded, are routinely used in a fixed facility, or that have been approved for full-rate production and for which procurement funding is anticipated in the current fiscal year or subsequent fiscal years. These funds will support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products. Efforts address the Military Health System Concept of Operations documents and follow-on Capabilities Based Assessments/Joint Capability Documents, appropriate Component requirements, legislative and Executive directives, and others as appropriate. Coordination occurs through the planning and execution activities of the Defense Health Agency Component Acquisition Executive (DHA CAE).

B. Program Change Summary (\$ in Millions)

	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Previous President's Budget	17.215	17.619	17.971	-	17.971
Current President's Budget	17.215	17.619	17.971	-	17.971
Total Adjustments	0.000	0.000	0.000	-	0.000
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-	0.000			

Change Summary Explanation

N/A

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency **Date:** April 2022

Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>	Project (Number/Name) 377A / <i>GDF-Medical Products and Capabilities Enhancement Activities</i>
--	---	--

COST (\$ in Millions)	Prior Years	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total	FY 2024	FY 2025	FY 2026	FY 2027	Cost To Complete	Total Cost
<i>377A: GDF-Medical Products and Capabilities Enhancement Activities</i>	45.971	17.215	17.619	17.971	0.000	17.971	18.330	18.697	19.071	19.452	Continuing	Continuing

A. Mission Description and Budget Item Justification

Guidance for Medical Products and Capabilities Enhancement Activity: This funding supports enhancement of existing medical products and medically related information technology systems to further fielding of joint medical materiel capabilities to meet Warfighter needs through support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2021	FY 2022	FY 2023 Base	FY 2023 OCO	FY 2023 Total
Title: 377A: GDF – Medical Products and Capabilities Enhancement Activities	17.215	17.619	17.971	0.000	17.971
Description: This funding provides support for developmental efforts to upgrade medical products and capabilities that have been fielded or have received approval for full rate production and anticipate production funding in the current or subsequent fiscal year. These funds will support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products.					
FY 2022 Plans: Funding will be used to modernize and upgrade products through joint testing and evaluation to improve fielding of medical materiel products. Significant FY22 Programs: Continuing efforts for Medical Device Modernization & Obsolescence Management across three tiers; Adenovirus Vaccine – Modernized Production intends to award a follow-on contract to optimize vaccine manufacturing. Other efforts for enhancement include: Austere Resuscitative Care Capability; Noncompressible Hemorrhage Control (NHC); Bubble Enhanced Focused Assessment with Sonography in Trauma (BE-FAST) Project; Detecting Asynchrony and Risk of Aspiration (DARS); T&E of Submarine Rescue Systems Decompression Plan; Soldier Optimization Decision Aids (SODA) Upgrades ; Heat Optimization Decision Aids (HODA) Upgrades; Canine Thermal Monitor (CTM); Integration of					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2023 Defense Health Agency				Date: April 2022	
Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>	Project (Number/Name) 377A / <i>GDF-Medical Products and Capabilities Enhancement Activities</i>			
B. Accomplishments/Planned Programs (\$ in Millions)					
Sensor Technology into Class I Socket in Support of Advanced Prosthetics & Amputee User Interface; and Brain Hemorrhage Detector Modernization.					
FY 2023 Base Plans: FY 2023 plans continue efforts outlined in FY2022 and support upgrades necessary to modernize Adenovirus manufacturing obsolescence of fielded medical equipment and devices.					
FY 2023 OCO Plans: N/A					
FY 2022 to FY 2023 Increase/Decrease Statement: Pricing adjustment for inflation.					
Accomplishments/Planned Programs Subtotals					
	17.215	17.619	17.971	0.000	17.971
C. Other Program Funding Summary (\$ in Millions)					
N/A					
Remarks					
D. Acquisition Strategy					
This program will integrate product improvements and enhancements resulting from post marketing studies and surveillance in existing medical products and medically related information technology systems to better meet Warfighter needs.					